Total Payments
$401,966
2024 Payments
$7,004
Companies
11
Transactions
575
Medicare Patients
477
Medicare Billing
$339,004
Payment Breakdown by Category
Other$339,460 (84.5%)
Travel$25,355 (6.3%)
Consulting$13,748 (3.4%)
Food & Beverage$12,385 (3.1%)
Research$11,009 (2.7%)
Education$8.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $339,375 | 210 | 84.4% |
| Travel and Lodging | $25,355 | 127 | 6.3% |
| Consulting Fee | $13,748 | 23 | 3.4% |
| Food and Beverage | $12,385 | 210 | 3.1% |
| Unspecified | $11,009 | 2 | 2.7% |
| Grant | $85.45 | 2 | 0.0% |
| Education | $8.00 | 1 | 0.0% |
Payments by Type
General
$390,957
573 transactions
Research
$11,009
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $96,091 | 155 | $0 (2024) |
| ABBVIE INC. | $81,730 | 111 | $0 (2024) |
| Teva Pharmaceuticals USA, Inc. | $60,171 | 88 | $0 (2022) |
| Biohaven Pharmaceuticals, Inc. | $57,737 | 73 | $0 (2021) |
| Biohaven Pharmaceutical Holding Company Ltd. | $34,189 | 38 | $0 (2022) |
| Allergan, Inc. | $28,618 | 41 | $0 (2021) |
| Amgen Inc. | $27,327 | 36 | $0 (2023) |
| Eli Lilly and Company | $11,009 | 2 | $0 (2021) |
| Lundbeck LLC | $4,362 | 17 | $0 (2023) |
| Ipsen Innovation | $515.00 | 4 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $7,004 | 12 | ABBVIE INC. ($6,812) |
| 2023 | $13,359 | 31 | ABBVIE INC. ($12,535) |
| 2022 | $85,107 | 113 | ABBVIE INC. ($46,338) |
| 2021 | $122,396 | 147 | Biohaven Pharmaceuticals, Inc. ($57,737) |
| 2020 | $89,765 | 134 | Lilly USA, LLC ($30,695) |
| 2019 | $73,907 | 119 | Teva Pharmaceuticals USA, Inc. ($32,835) |
| 2018 | $10,006 | 17 | Teva Pharmaceuticals USA, Inc. ($9,735) |
| 2017 | $421.86 | 2 | Teva Pharmaceuticals USA, Inc. ($421.86) |
All Payment Transactions
575 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | ABBVIE INC. | UBRELVY (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | ABBVIE INC. | UBRELVY (Drug) | Travel and Lodging | In-kind items and services | $40.33 | General |
| Category: NEUROSCIENCE | ||||||
| 11/18/2024 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $0.02 | General |
| Category: NEUROSCIENCE | ||||||
| 11/15/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $33.25 | General |
| Category: PAIN | ||||||
| 11/14/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: NEUROSCIENCE | ||||||
| 11/13/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $122.90 | General |
| Category: NEUROSCIENCE | ||||||
| 09/04/2024 | ABBVIE INC. | QULIPTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,250.00 | General |
| Category: NEUROSCIENCE | ||||||
| 08/15/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $28.80 | General |
| Category: PAIN | ||||||
| 08/13/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $56.13 | General |
| Category: Neuroscience | ||||||
| 08/08/2024 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $23.58 | General |
| Category: NEUROSCIENCE | ||||||
| 02/13/2024 | PFIZER INC. | NURTEC ODT (Drug) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: PAIN | ||||||
| 01/29/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $49.50 | General |
| Category: Neuroscience | ||||||
| 12/18/2023 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $4.12 | General |
| Category: PAIN | ||||||
| 12/11/2023 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $4.75 | General |
| Category: PAIN | ||||||
| 11/29/2023 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $25.80 | General |
| Category: NEUROLOGY | ||||||
| 11/17/2023 | ABBVIE INC. | QULIPTA (Drug) | Food and Beverage | In-kind items and services | $120.56 | General |
| Category: NEUROSCIENCE | ||||||
| 11/11/2023 | Ipsen Innovation | Dysport (Drug) | Food and Beverage | In-kind items and services | $147.50 | General |
| Category: Neurology | ||||||
| 11/11/2023 | Ipsen Innovation | Dysport (Drug) | Food and Beverage | In-kind items and services | $147.50 | General |
| Category: Neurology | ||||||
| 11/09/2023 | Ipsen Innovation | Dysport (Drug) | Travel and Lodging | In-kind items and services | $110.00 | General |
| Category: Neurology | ||||||
| 11/09/2023 | Ipsen Innovation | Dysport (Drug) | Travel and Lodging | In-kind items and services | $110.00 | General |
| Category: Neurology | ||||||
| 09/06/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: NEUROSCIENCE | ||||||
| 08/22/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $31.40 | General |
| Category: NEUROSCIENCE | ||||||
| 07/24/2023 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $30.60 | General |
| Category: PAIN | ||||||
| 07/12/2023 | PFIZER INC. | COMIRNATY (Biological), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: VACCINES | ||||||
| 07/11/2023 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: NEUROSCIENCE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | Eli Lilly and Company | $11,009 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 144 | 18,687 | $268,139 | $108,366 |
| 2022 | 4 | 123 | 16,644 | $225,862 | $93,457 |
| 2021 | 3 | 94 | 13,365 | $176,997 | $75,651 |
| 2020 | 7 | 116 | 10,193 | $169,346 | $61,531 |
Total Patients
477
Total Services
58,889
Medicare Billing
$339,004
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2023 | 34 | 18,481 | $166,320 | $86,066 | 51.7% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2023 | 34 | 93 | $48,639 | $11,243 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 52 | 85 | $36,380 | $7,840 | 21.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 28 | $16,800 | $3,216 | 19.1% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2022 | 34 | 16,490 | $148,410 | $76,187 | 51.3% |
| 64615 | Injection of chemical for paralysis of facial and neck nerve muscles on both sides of face | Office | 2022 | 35 | 84 | $43,596 | $9,961 | 22.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 35 | 46 | $19,504 | $3,873 | 19.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 19 | 24 | $14,352 | $3,435 | 23.9% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2021 | 27 | 13,245 | $119,205 | $63,195 | 53.0% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2021 | 26 | 66 | $34,518 | $7,989 | 23.1% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 41 | 54 | $23,274 | $4,467 | 19.2% |
| J0585 | Injection, onabotulinumtoxina, 1 unit | Office | 2020 | 23 | 10,000 | $90,000 | $43,860 | 48.7% |
| 64615 | Injection of chemical for destruction of facial and neck nerve muscles on both sides of face | Office | 2020 | 23 | 50 | $24,400 | $5,597 | 22.9% |
| 64405 | Injection of anesthetic agent and/or steroid into greater occipital nerve of upper neck and back of head | Office | 2020 | 11 | 74 | $25,506 | $4,640 | 18.2% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 21 | 27 | $12,528 | $3,105 | 24.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 11 | 11 | $7,271 | $1,685 | 23.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 15 | 18 | $6,228 | $1,467 | 23.6% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 12 | 13 | $3,413 | $1,177 | 34.5% |
About Dr. Herbert Krob, MD
Dr. Herbert Krob, MD is a Neuromuscular Medicine healthcare provider based in Portland, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/06/2006. The National Provider Identifier (NPI) number assigned to this provider is 1780615625.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Herbert Krob, MD has received a total of $401,966 in payments from pharmaceutical and medical device companies, with $7,004 received in 2024. These payments were reported across 575 transactions from 11 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($339,375).
As a Medicare-enrolled provider, Krob has provided services to 477 Medicare beneficiaries, totaling 58,889 services with total Medicare billing of $339,004. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Neuromuscular Medicine
- Other Specialties Neurology, Neurology
- Location Portland, OR
- Active Since 07/06/2006
- Last Updated 03/19/2021
- Taxonomy Code 2084N0008X
- Entity Type Individual
- NPI Number 1780615625
Products in Payments
- NURTEC ODT (Drug) $92,110
- UBRELVY (Drug) $76,432
- AJOVY (Drug) $42,570
- EMGALITY (Drug) $40,104
- QULIPTA (Drug) $33,088
- REYVOW (Drug) $27,693
- Aimovig (Biological) $27,304
- AJOVY (Biological) $17,088
- VYEPTI (Biological) $4,362
- Dysport (Drug) $515.00
- BOTOX (Drug) $448.21
- BOTOX (Biological) $380.04
- TEV-48125 (Biological) $376.86
- COMIRNATY (Biological) $32.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.